MA51139A - Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer - Google Patents

Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer

Info

Publication number
MA51139A
MA51139A MA051139A MA51139A MA51139A MA 51139 A MA51139 A MA 51139A MA 051139 A MA051139 A MA 051139A MA 51139 A MA51139 A MA 51139A MA 51139 A MA51139 A MA 51139A
Authority
MA
Morocco
Prior art keywords
piperidinocarbonylmethyl
cancer
treatment
oxopiperazine derivatives
oxopiperazine
Prior art date
Application number
MA051139A
Other languages
English (en)
Inventor
Valentino Cattori
Cyril Cook
Kevin R D Johnson
Matinder Kaur
Ulrich Kessler
Marc Labelle
Jean-D'amour K Twibanire
Farman Ullah
Ramkrishna Reddy Vakiti
Original Assignee
Inthera Bioscience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inthera Bioscience AG filed Critical Inthera Bioscience AG
Publication of MA51139A publication Critical patent/MA51139A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MA051139A 2017-12-15 2018-12-17 Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer MA51139A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599336P 2017-12-15 2017-12-15
CH1522018 2018-02-08

Publications (1)

Publication Number Publication Date
MA51139A true MA51139A (fr) 2020-10-21

Family

ID=65003562

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051139A MA51139A (fr) 2017-12-15 2018-12-17 Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer

Country Status (16)

Country Link
US (4) US10710975B2 (fr)
EP (1) EP3724178B1 (fr)
JP (1) JP7307744B2 (fr)
KR (2) KR20250078596A (fr)
CN (1) CN111788191B (fr)
AU (1) AU2018386327B2 (fr)
BR (1) BR112020011925A2 (fr)
CA (1) CA3085481A1 (fr)
IL (1) IL275337B2 (fr)
MA (1) MA51139A (fr)
MX (1) MX2020006219A (fr)
RU (1) RU2020123261A (fr)
SG (1) SG11202005365WA (fr)
TW (1) TWI810229B (fr)
WO (1) WO2019118973A1 (fr)
ZA (1) ZA202003554B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307744B2 (ja) * 2017-12-15 2023-07-12 インセラ バイオサイエンス アーゲー がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体
WO2020048829A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de 3,9-diazaspiro[5.5]undécane
WO2020048831A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one
WO2020048827A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de la 1,3,9-triazaspiro[5.5]undécan-2-one
WO2020048830A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one
WO2020048828A1 (fr) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane
WO2020048826A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de la 1-oxa-3,9-diazaspiro[5.5]undécan-2-one substituée en position 5
WO2021144302A1 (fr) * 2020-01-13 2021-07-22 Inthera Bioscience AG Biomarqueurs pour déterminer la sensibilité à des dérivés d'oxopipérazine et leurs méthodes d'utilisation
EP4168014A1 (fr) * 2020-06-19 2023-04-26 Inthera Bioscience AG Dérivés d'oxopipérazine pour le traitement du cancer
JPWO2022138944A1 (fr) * 2020-12-25 2022-06-30
WO2024015229A1 (fr) * 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Charges utiles-lieurs clivables par une protéase/enzyme et conjugués protéiques
CN119816490A (zh) * 2022-09-16 2025-04-11 先正达农作物保护股份公司 杀有害生物活性的环胺化合物
IL324503A (en) 2023-05-26 2026-01-01 Inthera Bioscience AG Oxopiperazine derivatives for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885995A (en) 1996-04-03 1999-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2458009C (fr) 2001-08-24 2011-08-16 Yale University Composes de piperazinone utilises comme agents antitumoraux et anticancereux et procedes de traitement
AR036812A1 (es) * 2001-10-17 2004-10-06 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes
CL2003002356A1 (es) * 2002-11-18 2005-02-11 Schering Corp Compuestos derivados de 1-(1-acetil-piperidin-4-il)-(ester o amida)-4-(bencidrilo sustituido)-2-tert-butil-piperazina, composicion farmaceutica, y su uso en la inhibicion de 17b-hidroxiesteroide deshidrogenasa de tipo 3 y de enfermedades que dependen
US20060094726A1 (en) 2003-01-30 2006-05-04 Jeffrey Kerns Quinoline derivatives as nk-2 and nk-3 receptor antagonists
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
EP1909797A4 (fr) * 2005-08-02 2013-02-27 Neurogen Corp Dipipérazinyl cétones et analogues apparentés
CN101341123A (zh) * 2005-12-21 2009-01-07 因塞特公司 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺
EP2889295A1 (fr) 2010-08-12 2015-07-01 New York University Oligooxopiperazines et procédés de fabrication et d'utilisation de celles-ci
EP2699568A1 (fr) * 2011-04-21 2014-02-26 Piramal Enterprises Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
CN104470903B (zh) 2012-01-25 2017-02-22 诺华股份有限公司 杂环化合物和它们的使用方法
EP2814821B1 (fr) 2012-02-16 2018-04-25 New York University Contrôle de l'expression génique induite par l'hypoxie avec des mimétiques hélicoïdaux non peptidiques d'oligo-oxopipérazine
WO2014113794A2 (fr) 2013-01-19 2014-07-24 New York University Oligooxopipérazines pour la réactivation du p53
US11180481B2 (en) 2014-04-15 2021-11-23 New York University Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction
US10787424B2 (en) * 2014-05-21 2020-09-29 New York University Oxopiperazine helix mimetics for control of Hypoxia-Inducible gene expression
JP7307744B2 (ja) 2017-12-15 2023-07-12 インセラ バイオサイエンス アーゲー がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体
WO2021144302A1 (fr) 2020-01-13 2021-07-22 Inthera Bioscience AG Biomarqueurs pour déterminer la sensibilité à des dérivés d'oxopipérazine et leurs méthodes d'utilisation
EP4168014A1 (fr) 2020-06-19 2023-04-26 Inthera Bioscience AG Dérivés d'oxopipérazine pour le traitement du cancer

Also Published As

Publication number Publication date
US10710975B2 (en) 2020-07-14
SG11202005365WA (en) 2020-07-29
KR102811956B1 (ko) 2025-05-23
IL275337B2 (en) 2024-06-01
JP2021506973A (ja) 2021-02-22
AU2018386327A1 (en) 2020-06-25
RU2020123261A3 (fr) 2022-02-16
KR20200101397A (ko) 2020-08-27
US20200308139A1 (en) 2020-10-01
CA3085481A1 (fr) 2019-06-20
WO2019118973A1 (fr) 2019-06-20
TWI810229B (zh) 2023-08-01
EP3724178A1 (fr) 2020-10-21
RU2020123261A (ru) 2022-01-17
US20220213057A1 (en) 2022-07-07
TW201930286A (zh) 2019-08-01
KR20250078596A (ko) 2025-06-02
CN111788191A (zh) 2020-10-16
MX2020006219A (es) 2020-12-03
IL275337B1 (en) 2024-02-01
EP3724178B1 (fr) 2024-05-01
CN111788191B (zh) 2024-06-04
JP7307744B2 (ja) 2023-07-12
BR112020011925A2 (pt) 2020-11-24
ZA202003554B (en) 2024-11-27
US11306068B2 (en) 2022-04-19
US12012393B2 (en) 2024-06-18
US20250115571A1 (en) 2025-04-10
IL275337A (en) 2020-07-30
US20190185449A1 (en) 2019-06-20
AU2018386327B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3781564C0 (fr) Dérivés de pyridazine pour le traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3634417A4 (fr) Dérivés quinazoline-pyrazole pour le traitement de troubles liés au cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3454896A4 (fr) Dérivés hétérocycliques pour le traitement de rsv
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer